NFIX and prostate carcinoma: Regarding NFIX, 22 datasets revealed lower NFIX expression levels in 10 types of carcinomas with statistical significance, however, 10 analyses showed higher NFIX expression levels in brain and CNS cancer, esophageal cancer, melanoma, prostate cancer and sarcoma.